| 產品編號 | BIO0875SM |
| 英文名稱 | Anti-human NaPi2b / SLC34A2 (Lifastuzumab vedotin Biosimilar) |
| 中文名稱 | |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應 | Human |
| 產品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG1 |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 | |
| 產品圖片 |
Human NaPi2b HEK293 Cell Line were stained with Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin)and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.9793 ug/mL.
Human NaPi2b CHO-S Cells were stained with Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS
The drug-to-antibody ratio (DAR) of the Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is 3.7.
The purity of Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) is more than 95%, determined by SEC-HPLC.
Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
